John K Forrest1, Ryan K Kaple2, Gilbert H L Tang3, Steven J Yakubov4, Tamim M Nazif5, Mathew R Williams6, Angie Zhang7, Jeffrey J Popma8, Michael J Reardon9. 1. Department of Internal Medicine (Cardiology), Yale University School of Medicine, New Haven, Connecticut. Electronic address: john.k.forrest@yale.edu. 2. Department of Internal Medicine (Cardiology), Yale University School of Medicine, New Haven, Connecticut. 3. Department of Cardiovascular Surgery, Mount Sinai Medical Center, New York, New York. 4. Department of Cardiology, Riverside Methodist - Ohio Health, Columbus, Ohio. 5. Department of Cardiology, Columbia University Medical Center, New York, New York. 6. Department of Cardiothoracic Surgery, New York University-Langone Medical Center, New York, New York. 7. Department of Statistical Services, Medtronic, Minneapolis, Minnesota. 8. Department of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. 9. Department of Cardiovascular Surgery, Houston Methodist DeBakey Heart and Vascular Institute, Houston, Texas.
Abstract
OBJECTIVES: The aim of this study was to assess the evolution of early outcomes for 3 iterative self-expanding transcatheter aortic valves. BACKGROUND: Over the past decade there have been rapid advancements in transcatheter aortic valve replacement (TAVR) technologies, including 3 generations of supra-annular self-expanding transcatheter systems. METHODS: Data from the Society of Thoracic Surgeons/American College of Cardiology TVT (Transcatheter Valve Therapy) Registry for patients undergoing TAVR with CoreValve, Evolut R, or Evolut PRO valves to treat tricuspid aortic stenosis between January 2014 and September 2017 were obtained. Patient risk and echocardiographic data are site reported. Valves analyzed included 23-, 26-, and 29-mm sizes to fit 18- to 26-mm annular diameters. Propensity score matching was performed using the Evolut PRO group as the common reference. RESULTS: Of 18,874 patients undergoing TAVR at 381 centers, 5,514 patients were implanted with CoreValve, 11,295 with Evolut R, and 2,065 with Evolut PRO valves. At 30 days, there were significantly fewer patients with more than mild aortic regurgitation for the unmatched (7.8% CoreValve, 5.2% Evolut R, and 2.8% Evolut PRO; p < 0.001) and matched populations (8.3% CoreValve, 5.4% Evolut R, and 3.4% Evolut PRO; p = 0.032). The mean aortic valve gradients at 30 days in the matched populations were <8 mm Hg for all 3 valves (7.3 mm Hg CoreValve, 7.5 mm Hg Evolut R, 7.2 mm Hg Evolut PRO). CONCLUSIONS: Advancements in transcatheter valve technologies and expanding indications for TAVR have resulted in improved outcomes for patients undergoing TAVR in the United States with self-expanding, supra-annular valves. In particular, the addition of an outer pericardial tissue wrap designed to enhance sealing at the level of the aortic annulus has resulted in very low rates of significant aortic regurgitation while maintaining excellent hemodynamic status.
OBJECTIVES: The aim of this study was to assess the evolution of early outcomes for 3 iterative self-expanding transcatheter aortic valves. BACKGROUND: Over the past decade there have been rapid advancements in transcatheter aortic valve replacement (TAVR) technologies, including 3 generations of supra-annular self-expanding transcatheter systems. METHODS: Data from the Society of Thoracic Surgeons/American College of Cardiology TVT (Transcatheter Valve Therapy) Registry for patients undergoing TAVR with CoreValve, Evolut R, or Evolut PRO valves to treat tricuspid aortic stenosis between January 2014 and September 2017 were obtained. Patient risk and echocardiographic data are site reported. Valves analyzed included 23-, 26-, and 29-mm sizes to fit 18- to 26-mm annular diameters. Propensity score matching was performed using the Evolut PRO group as the common reference. RESULTS: Of 18,874 patients undergoing TAVR at 381 centers, 5,514 patients were implanted with CoreValve, 11,295 with Evolut R, and 2,065 with Evolut PRO valves. At 30 days, there were significantly fewer patients with more than mild aortic regurgitation for the unmatched (7.8% CoreValve, 5.2% Evolut R, and 2.8% Evolut PRO; p < 0.001) and matched populations (8.3% CoreValve, 5.4% Evolut R, and 3.4% Evolut PRO; p = 0.032). The mean aortic valve gradients at 30 days in the matched populations were <8 mm Hg for all 3 valves (7.3 mm Hg CoreValve, 7.5 mm Hg Evolut R, 7.2 mm Hg Evolut PRO). CONCLUSIONS: Advancements in transcatheter valve technologies and expanding indications for TAVR have resulted in improved outcomes for patients undergoing TAVR in the United States with self-expanding, supra-annular valves. In particular, the addition of an outer pericardial tissue wrap designed to enhance sealing at the level of the aortic annulus has resulted in very low rates of significant aortic regurgitation while maintaining excellent hemodynamic status.
Authors: Teresa Alvarado; Fernando Rivero; Guillermo Diego; Marcos García-Guimaraes; Jorge Salamanca; Pablo Díez-Villanueva; Javier Cuesta; Paula Antuña; Jesús Jiménez-Borreguero; Fernando Alfonso Journal: J Thorac Dis Date: 2021-07 Impact factor: 2.895
Authors: Francesco Moroni; Lorenzo Azzalini; Lars Sondergaard; Guilherme F Attizzani; Santiago García; Hani Jneid; Mamas A Mamas; Rodrigo Bagur Journal: J Am Heart Assoc Date: 2022-06-14 Impact factor: 6.106
Authors: Luis Augusto P Dallan; John K Forrest; Michael J Reardon; Wilson Y Szeto; Isaac George; Susheel Kodali; Neal S Kleiman; Steven J Yakubov; Kendra J Grubb; Fang Liu; Cristian Baeza; Guilherme F Attizzani Journal: J Am Heart Assoc Date: 2021-09-13 Impact factor: 5.501
Authors: Jie Li; Yinghao Sun; Shengneng Zheng; Guang Li; Haojian Dong; Ming Fu; Yujing Mo; Yi Li; Huadong Liu; Zhaoyan Xu; Liting Zhang; Yong Cao; Ruixin Fan; D Scott Lim; Jianfang Luo Journal: Front Cardiovasc Med Date: 2021-07-12